01—Abstract
Summary
Summary of the 10-K filed February 26, 2010. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences Corporation (EW) reported strong performance in its 2009 10-K filing, highlighting significant growth driven by its Heart Valve Therapy segment, particularly the SAPIEN transcatheter heart valve and advanced surgical valves.
The company demonstrated robust revenue growth of 6.8% year-over-year to $1.32 billiona, with international markets contributing a substantial 58% of total sales. The company's commitment to research and development is evident, with a 13.3% increase in R&D spending to $175.5 million, focused on expanding its transcatheter valve technology and critical care monitoring systems. Despite global economic headwinds, Edwards Lifesciences maintained healthy gross profit margins around 70% and managed its selling, general, and administrative expenses effectively.
The company also repurchased stock and maintained a strong liquidity position with a $500 millionb revolving credit facility. Overall, the filing paints a picture of a leading medical technology company with a strong product pipeline, effective execution, and a clear strategy for future growth in the cardiovascular disease treatment market.
02—Key points
Key Highlights
- Revenue grew by 6.8% to $1.32 billion in 2009, driven by strong performance in Heart Valve Therapy and international markets.
- Heart Valve Therapy segment sales increased by 17.7% to $714.9 million, fueled by the Edwards SAPIEN transcatheter heart valve and new surgical valve launches.
- Research and Development expenses increased by 26% to $175.5 million, reflecting continued investment in innovation, particularly in transcatheter valve technologies.
- Gross profit margin remained strong at 69.8%, indicating efficient operations and pricing power.
- International sales represented 58% of total net sales, demonstrating the company's global reach and diversified revenue streams.
- The company maintained a healthy liquidity position, with $334.1 million in cash and cash equivalents and $500 million available under its revolving credit facility.
- The company repurchased $95.5 million of its common stock in 2009, signaling confidence in its financial health and value.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2009filed February 26, 2010Financial Statements
FY2009 against FY2008
| Line item | FY2009FY2008 | Change |
|---|---|---|
| Revenue | $1.32B$1.24B | +6.8% |
| Cost of Revenue | $399.10M$419.60M | −4.9% |
| Gross Profit | $922.30M$818.10M | +12.7% |
| R&D Expenses | $175.50M$139.20M | +26.1% |
| SG&A Expenses | $508.80M$480.60M | +5.9% |
| Interest Expense | $2.70M$7.20M | −62.5% |
| Net Income | $229.10M$128.90M | +77.7% |
| EPS (Basic) | $0.34$0.19 | +77.4% |
| EPS (Diluted) | $0.33$0.18 | +77.3% |
| Shares Outstanding (Basic) | 675.00M670.20M | +0.7% |
| Shares Outstanding (Diluted) | 705.00M715.20M | −1.4% |
05—Questions
Frequently Asked Questions
What was Edwards Lifesciences' revenue growth in 2009, and what were the key drivers?
Edwards Lifesciences reported a 6.8% increase in net sales for 2009, reaching $1.32 billion. The primary driver was the Heart Valve Therapy segment, which saw a 17.7% increase in sales to $714.9 million, largely due to the success of the Edwards SAPIEN transcatheter heart valve and new surgical valve products. International markets also played a significant role, accounting for 58% of total sales.
How did the company's investment in Research and Development (R&D) change, and where was it focused?
Edwards Lifesciences significantly increased its R&D investment by 26% in 2009, totaling $175.5 million. This investment was strategically focused on advancing its transcatheter heart valve technologies (like the SAPIEN and SAPIEN XT systems) and developing new solutions in the Critical Care segment, such as enhanced hemodynamic monitoring and glucose monitoring technologies.
What is the company's financial position regarding debt and liquidity?
The company maintained a strong financial position in 2009. It had $334.1 million in cash and cash equivalents and access to a $500 million unsecured revolving credit facility. Long-term debt was relatively low at $90.3 million, indicating a well-managed balance sheet.
What are the main product categories for Edwards Lifesciences?
Edwards Lifesciences' business is organized into four main product categories: Heart Valve Therapy (surgical tissue valves, repair products, and transcatheter valves), Critical Care (hemodynamic monitoring equipment), Cardiac Surgery Systems (products used during cardiac surgery), and Vascular (products for treating peripheral vascular disease).
06—Continue